{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:54:50Z","timestamp":1768294490149,"version":"3.49.0"},"reference-count":50,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,1]]},"abstract":"<jats:p>Objective. Influenza-associated deaths in healthy children that were reported during the 2003\u20132004 influenza season heightened the public awareness of the seriousness of influenza in children. In 1996\u20131998, a pivotal phase III trial was conducted in children who were 15 to 71 months of age. Live attenuated influenza vaccine, trivalent (LAIV-T), was shown to be safe and efficacious. In a subsequent randomized, double-blind, placebo-controlled LAIV-T trial in children who were 1 to 17 years of age, a statistically significant increase in asthma encounters was observed for children who were younger than 59 months. LAIV-T was not licensed to children who were younger than 5 years because of the concern for asthma. We report on the largest safety study to date of the recently licensed LAIV-T in children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a 4-year (1998\u20132002) community-based trial that was conducted at Scott &amp; White Memorial Hospital and Clinic (Temple, TX).<\/jats:p><jats:p>Methods. An open-label, nonrandomized, community-based trial of LAIV-T was conducted before its licensure. Medical records of all children were surveyed for serious adverse events (SAEs) 6 weeks after vaccination. Health care utilization was evaluated by determining the relative risk (RR) of medically attended acute respiratory illness (MAARI) and asthma rates at 0 to 14 and 15 to 42 days after vaccination compared with the rates before vaccination. Medical charts of all visits coded as asthma were reviewed for appropriate classification of events: acute asthma or other. We evaluated the risk for MAARI (health care utilization for acute respiratory illness) 0 to 14 and 15 to 42 days after LAIV-T by a method similar to the postlicensure safety analysis conducted on measles, mumps, and rubella and on diphtheria, tetanus, and whole-cell pertussis vaccines.<\/jats:p><jats:p>Results. All children regardless of age were administered a single intranasal dose of LAIV-T in each vaccine year. In the 4 years of the study, we administered 18780 doses of LAIV-T to 11096 children. A total of 4529, 7036, and 7215 doses of LAIV-T were administered to children who were 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age, respectively. In vaccination years 1, 2, 3, and 4, we identified 10, 15, 11, and 6 SAEs, respectively. None of the SAEs was attributed to LAIV-T. In vaccination years 1, 2, 3, and 4, we identified 3, 2, 1, and 0 pregnancies, respectively, among adolescents. All delivered healthy infants. The RR for MAARI from 0 to 14 and 15 to 42 days after LAIV-T was assessed in vaccinees during the 4 vaccine years. Compared with the prevaccination period, there was no significant increase in risk in health care utilization attributed to MAARI from 0 to 14 and 15 to 42 days after vaccination in children who were 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in the 4 vaccine years. In children who were 18 months to 4 years of age, there was no significant increase in the risk in health care utilization for MAARI, MAARI subcategories (otitis media\/sinusitis, upper respiratory tract illness, and lower respiratory tract illness), and asthma during the 0 to 14 days after vaccination compared with the prevaccination period. No significant increase in the risk in health care utilization for MAARI, MAARI subcategories, and asthma was detected when the risk period was extended to 15 to 42 days after vaccination, except for asthma events in vaccine year 1. A RR of 2.85 (95% confidence interval [CI]: 1.01\u20138.03) for asthma events was detected in children who were 18 months to 4 years of age but was not significantly increased for the other 3 vaccine years (vaccine year 2, RR: 1.42 [95% CI: 0.59\u20133.42]; vaccine year 3, RR: 0.47 [95% CI: 0.12\u20131.83]; vaccine year 4, RR: 0.20 [95% CI: 0.03\u20131.54]). No significant increase in the risk in health care utilization for MAARI or asthma was observed in children who were 18 months to 18 years of age and received 1, 2, 3, or 4 annual sequential doses of LAIV-T. Children who were 18 months to 4 years of age and received 1, 2, 3, or 4 annual doses of LAIV-T did not experience a significant increase in the RR for MAARI 0 to 14 days after vaccination; this was also true for children who were 5 to 9 and 10 to 18 years of age.<\/jats:p><jats:p>Conclusions. We observed no increased risk for asthma events 0 to 14 days after vaccination in children who were 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age, In vaccine year 1, children who were 18 months to 4 years of age did have a significantly higher RR (2.85; 95% CI: 1.01\u20138.03) for asthma events 15 to 42 days after vaccination. In vaccine year 2, the formulation of LAIV-T was identical to the vaccine formulation used in vaccine year 1; however, in children who were 18 months to 4 years of age, no statistically significant increased risk was detected for asthma events 15 to 42 days after vaccination. Similarly, in vaccine years 3 and 4, children who were 18 months to 4 years of age did not have a statistically significant increased risk for asthma events 15 to 42 days after vaccination. Also, LAIV-T did not increase the risk for asthma in children who received 1, 2, 3, or 4 annual doses of LAIV-T. Although the possibility for a true increased risk for asthma was observed in 1 of 4 years in children who were 18 months to 4 years at 15 to 42 days after vaccination, it is more likely that the association is a chance effect because of the 190 comparisons made without adjustment for multiple comparisons. We conclude that LAIV-T is safe in children who are 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age. The hypothesis that LAIV-T is associated with an increase in asthma events in children who are younger than 5 years is not supported by our data. Reassessment of the lower age limit for use of LAIV-T in children is indicated.<\/jats:p>","DOI":"10.1542\/peds.2004-2258","type":"journal-article","created":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:36:02Z","timestamp":1125534962000},"page":"e397-e407","source":"Crossref","is-referenced-by-count":82,"title":["Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial"],"prefix":"10.1542","volume":"116","author":[{"given":"Pedro A.","family":"Piedra","sequence":"first","affiliation":[{"name":"Departments of Molecular Virology and Microbiology"},{"name":"Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjusha J.","family":"Gaglani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Riggs","sequence":"additional","affiliation":[{"name":"Division of Research, Scott & White Memorial Hospital and Clinic, Temple, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayla","family":"Herschler","sequence":"additional","affiliation":[{"name":"Division of Research, Scott & White Memorial Hospital and Clinic, Temple, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Fewlass","sequence":"additional","affiliation":[{"name":"Division of Research, Scott & White Memorial Hospital and Clinic, Temple, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Watts","sequence":"additional","affiliation":[{"name":"Division of Research, Scott & White Memorial Hospital and Clinic, Temple, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Kozinetz","sequence":"additional","affiliation":[{"name":"Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Hessel","sequence":"additional","affiliation":[{"name":"MedImmune Vaccines, Mountain View, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Paul","family":"Glezen","sequence":"additional","affiliation":[{"name":"Departments of Molecular Virology and Microbiology"},{"name":"Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2005,9,1]]},"reference":[{"key":"2021120820020555500_R1","doi-asserted-by":"crossref","unstructured":"Michaud CM, Murray CJL, Bloom BR. Burden of disease\u2014implications for future research. JAMA.\u20082001;285:535\u2013539","DOI":"10.1001\/jama.285.5.535"},{"key":"2021120820020555500_R2","doi-asserted-by":"crossref","unstructured":"Glezen WP, Paredes A, Taber LH. Influenza in children. Relationship to other respiratory agents. JAMA.\u20081980;243:1345\u20131349","DOI":"10.1001\/jama.243.13.1345"},{"key":"2021120820020555500_R3","doi-asserted-by":"crossref","unstructured":"Sugaya N, Mitamura K, Nirasawa M, Takahashi K. The impact of winter epidemics of influenza and respiratory syncytial virus on paediatric admissions to an urban general hospital. J Med Virol.\u20082000;60:102\u2013106","DOI":"10.1002\/(SICI)1096-9071(200001)60:1<102::AID-JMV17>3.0.CO;2-D"},{"key":"2021120820020555500_R4","doi-asserted-by":"crossref","unstructured":"Chiu SS, Lau YL, Chan KH, Wong WHS, Peiris JSM. Influenza-related hospitalizations among children in Hong Kong. N Engl J Med.\u20082002;347:2097\u20132103","DOI":"10.1056\/NEJMoa020546"},{"key":"2021120820020555500_R5","doi-asserted-by":"crossref","unstructured":"Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980\u20131996. JAMA.\u20081999;282:1440\u20131446","DOI":"10.1001\/jama.282.15.1440"},{"key":"2021120820020555500_R6","doi-asserted-by":"crossref","unstructured":"Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med.\u20082000;342:232\u2013239","DOI":"10.1056\/NEJM200001273420402"},{"key":"2021120820020555500_R7","doi-asserted-by":"crossref","unstructured":"Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. The effects of influenza on hospitalization, outpatient visits, and courses of antibiotics in children. N Engl J Med.\u20082000;342:225\u2013231","DOI":"10.1056\/NEJM200001273420401"},{"key":"2021120820020555500_R8","doi-asserted-by":"crossref","unstructured":"Glezen WP, Decker M, Joseph SW, Mercready RG Jr. Acute respiratory disease associated with influenza epidemic in Houston, 1981\u20131983. J Infect Dis.\u20081987;155:1119\u20131126","DOI":"10.1093\/infdis\/155.6.1119"},{"key":"2021120820020555500_R9","doi-asserted-by":"crossref","unstructured":"Couch RB, Kasel JA, Glezen WP, et al. Influenza: its control in persons and populations. J Infect Dis.\u20081986;153:431\u2013440","DOI":"10.1093\/infdis\/153.3.431"},{"key":"2021120820020555500_R10","doi-asserted-by":"crossref","unstructured":"Jennings LC, Miles JAR. A study of acute respiratory disease in the community of Port Chalmers. II. Influenza A\/Port Chalmers\/1\/73: intrafamilial spread and the effect of antibodies to the surface antigens. J Hyg (Lond).\u20081978;81:67\u201375","DOI":"10.1017\/S0022172400053778"},{"key":"2021120820020555500_R11","doi-asserted-by":"crossref","unstructured":"Fox JP, Hall CE, Cooney MK, Foy HM. Influenzavirus infections in Seattle families, 1975\u20131979. I. Study design, methods, and the occurrence of infections by time and age. Am J Epidemiol.\u20081982;116:212\u2013227","DOI":"10.1093\/oxfordjournals.aje.a113407"},{"key":"2021120820020555500_R12","doi-asserted-by":"crossref","unstructured":"Fox JP, Cooney MK, Hall CE, Foy HM. Influenzavirus infections in Seattle families, 1975\u20131979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol.\u20081982;116:228\u2013242","DOI":"10.1093\/oxfordjournals.aje.a113408"},{"key":"2021120820020555500_R13","doi-asserted-by":"crossref","unstructured":"Frank AL, Taber LH, Wells JM. Comparison of infection rates and severity of illness for influenza A subtypes H1N1 and H3N2. J Infect Dis.\u20081985;151:73\u201380","DOI":"10.1093\/infdis\/151.1.73"},{"key":"2021120820020555500_R14","doi-asserted-by":"crossref","unstructured":"Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infection in infants. Pediatr Infect Dis J.\u20081997;16:1065\u20131068","DOI":"10.1097\/00006454-199711000-00012"},{"key":"2021120820020555500_R15","doi-asserted-by":"crossref","unstructured":"Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season. Arch Pediatr Adolesc Med.\u20082002;156:986\u2013991","DOI":"10.1001\/archpedi.156.10.986"},{"key":"2021120820020555500_R16","doi-asserted-by":"crossref","unstructured":"Neuzil KM, Wright PF, Mitchel EF, Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr.\u20082000;137:856\u2013864","DOI":"10.1067\/mpd.2000.110445"},{"key":"2021120820020555500_R17","doi-asserted-by":"crossref","unstructured":"Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions JAMA.\u20082000;283:499\u2013505","DOI":"10.1001\/jama.283.4.499"},{"key":"2021120820020555500_R18","unstructured":"Sperber SJ, Gross PA. Influenza: manifestations, treatment and prevention. Infect Med.\u20081994;11:675\u2013683"},{"key":"2021120820020555500_R19","doi-asserted-by":"crossref","unstructured":"Glezen WP. Consideration of the risk of influenza in children and indications for prophylaxis. Rev Infect Dis.\u20081980;2:408\u2013420","DOI":"10.1093\/clinids\/2.3.408"},{"key":"2021120820020555500_R20","doi-asserted-by":"crossref","unstructured":"O'Brien KL, Walters MI, Sellman J, et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis.\u20082000;30:784\u2013789","DOI":"10.1086\/313772"},{"key":"2021120820020555500_R21","doi-asserted-by":"crossref","unstructured":"Fujimoto S, Kobayashi M, Uemura O, et al. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet.\u20081998;352:873\u2013875","DOI":"10.1016\/S0140-6736(98)12449-2"},{"key":"2021120820020555500_R22","doi-asserted-by":"crossref","unstructured":"McCullers JA, Facchini S, Chesney PJ, Webster RG. Influenza B virus encephalitis. Clin Infect Dis.\u20081999;28:898\u2013900","DOI":"10.1086\/515214"},{"key":"2021120820020555500_R23","unstructured":"Centers for Disease Control and Prevention (CDC). Update: influenza-associated deaths reported among children aged &lt;18 years\u2014United States, 2003\u201304 influenza season. MMWR Morb Mortal Wkly Rep.\u20082004;52:1286\u20131288"},{"key":"2021120820020555500_R24","doi-asserted-by":"crossref","unstructured":"Belshe RB, Mendelman P, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med.\u20081998;338:1405\u20131412","DOI":"10.1056\/NEJM199805143382002"},{"key":"2021120820020555500_R25","doi-asserted-by":"crossref","unstructured":"Belshe RB, Gruber WC, Mendelman P, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A\/Sydney) not contained in the vaccine. J Pediatr.\u20082000;136:168\u2013175","DOI":"10.1016\/S0022-3476(00)70097-7"},{"key":"2021120820020555500_R26","doi-asserted-by":"crossref","unstructured":"Piedra PA, Yan L, Kotloff K, et al. Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in preschool aged children. Pediatrics.\u20082002;110:662\u2013672","DOI":"10.1542\/peds.110.4.662"},{"key":"2021120820020555500_R27","doi-asserted-by":"crossref","unstructured":"Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J.\u20082004;23:138\u2013144","DOI":"10.1097\/01.inf.0000109392.96411.4f"},{"key":"2021120820020555500_R28","doi-asserted-by":"crossref","unstructured":"Piedra PA, Gaglani M, Herschler G, et al. Safety and effectiveness of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children. In: Osterhaus ADME, ed. The World Congress on Options for the Control of Influenza IV. Amsterdam, Netherlands: Elsevier Science 2001;1219:939\u2013943","DOI":"10.1016\/S0531-5131(01)00019-X"},{"key":"2021120820020555500_R29","doi-asserted-by":"crossref","unstructured":"Halloran ME, Longini IM, Gaglani MJ, et al. Protection against influenza A (H1N1) and B by trivalent, cold-adapted, influenza virus vaccine (CAIV-T). Am J Epidemiol.\u20082003;158:305\u2013311","DOI":"10.1093\/aje\/kwg163"},{"key":"2021120820020555500_R30","doi-asserted-by":"crossref","unstructured":"Gaglani MJ, Piedra PA, Herschler GB, et al. Direct effectiveness of the trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against the 2000\u20132001 influenza A (H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med.\u20082004;158:65\u201373","DOI":"10.1001\/archpedi.158.1.65"},{"key":"2021120820020555500_R31","doi-asserted-by":"crossref","unstructured":"Griffin MR, Taylor JA, Daugherty JR, Ray WA. No increased risk for invasive bacterial infection found following diphtheria-tetanus-pertussis immunization. Pediatrics.\u20081992;89:640\u2013642","DOI":"10.1542\/peds.89.4.640"},{"key":"2021120820020555500_R32","doi-asserted-by":"crossref","unstructured":"Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W. Risk of seizure after measles-mumps-rubella immunization. Pediatrics.\u20081991;88:881\u2013885","DOI":"10.1542\/peds.88.5.881"},{"key":"2021120820020555500_R33","unstructured":"Selvin S. Poisson regression analysis. In: Selvin S, ed. Practical Biostatistical Methods. Belmont, CA: Duxbury Press; 1995"},{"key":"2021120820020555500_R34","doi-asserted-by":"crossref","unstructured":"Ledley FD, Brody B, Kozinetz CA, Mize S. The challenge of follow-up for clinical trials of somatic gene therapy. Hum Gene Ther.\u20081992;3:657\u2013663","DOI":"10.1089\/hum.1992.3.6-657"},{"key":"2021120820020555500_R35","unstructured":"Breslow N. Multivariate cohort analysis. Natl Cancer Inst Monogr.\u20081985;67:149\u2013156"},{"key":"2021120820020555500_R36","doi-asserted-by":"crossref","unstructured":"Whitaker-Dowling P, Maassab HF, Younger JS. Dominant-negative mutants as antiviral agents: simultaneous infection with the cold-adapted live-attenuated vaccine for influenza A protects ferrets from disease produced by wild-type influenza A. J Infect Dis.\u20081991;164:1200\u20131202","DOI":"10.1093\/infdis\/164.6.1200"},{"key":"2021120820020555500_R37","doi-asserted-by":"crossref","unstructured":"Younger JS, Treanor JJ, Betts RF, Whitaker-Dowling P. Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans. J Clin Microbiol.\u20081994;32:750\u2013754","DOI":"10.1128\/jcm.32.3.750-754.1994"},{"key":"2021120820020555500_R38","doi-asserted-by":"crossref","unstructured":"Maassab HF. Adaptation and growth characteristics of influenza virus at 25\u00b0C. Nature.\u20081967;213:612\u2013614","DOI":"10.1038\/213612a0"},{"key":"2021120820020555500_R39","doi-asserted-by":"crossref","unstructured":"Maassab HF, DeBorde DC. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine.\u20081985;3:355\u2013369","DOI":"10.1016\/0264-410X(85)90124-0"},{"key":"2021120820020555500_R40","doi-asserted-by":"crossref","unstructured":"Snyder MH, Betts RF, DeBorde DC, et al. Four viral genes independently contribute to attenuation of live A\/Ann Arbor\/6\/60 (H2N2) cold-adapted reassortant virus vaccine. J Virol.\u20081988;62:488\u2013495","DOI":"10.1128\/jvi.62.2.488-495.1988"},{"key":"2021120820020555500_R41","doi-asserted-by":"crossref","unstructured":"Donabedian AM, DeBorde DC, Cook S, Smitka CW, Maassab HF. A mutation in the PA protein gene of cold-adapted B\/Ann Arbor\/1\/66 influenza virus associated with reversion of temperature sensitivity and attenuated virulence. Virology.\u20081988;163:444\u2013451","DOI":"10.1016\/0042-6822(88)90285-1"},{"key":"2021120820020555500_R42","doi-asserted-by":"crossref","unstructured":"Shu LP, Sharp GB, Lin YP, et al. Genetic reassortment in pandemic and interpandemic influenza viruses. A study of 122 viruses infecting humans. Eur J Epidemiol.\u20081996;12:63\u201370","DOI":"10.1007\/BF00144430"},{"key":"2021120820020555500_R43","doi-asserted-by":"crossref","unstructured":"Xu X, Smith CB, Mungall BA, et al. Intercontinental circulation of human influenza A (H1N2) reassortant viruses during the 2001\u20132002 influenza season. J Infect Dis.\u20082002;186:1490\u20131493","DOI":"10.1086\/344738"},{"key":"2021120820020555500_R44","doi-asserted-by":"crossref","unstructured":"Ellis JS, Alvarez-Aguero A, Gregory V, Lin YP, Hay A, Zambon MC. Influenza AH1N2 viruses, United Kingdom, 2001\u201302 influenza season. Emerg Infect Dis.\u20082003;9:304\u2013310","DOI":"10.3201\/eid0903.020404"},{"key":"2021120820020555500_R45","doi-asserted-by":"crossref","unstructured":"Glezen WP, Piedra PA, Longini I, Halloran ME. Safety of cold-adapted live influenza vaccine [letter to editor]. Pediatr Infect Dis J.\u20082004;23:593\u2013594","DOI":"10.1097\/00006454-200406000-00030"},{"key":"2021120820020555500_R46","doi-asserted-by":"crossref","unstructured":"Zangwill KM, Droge J, Mendelman P, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among children. Pediatr Infect Dis J.\u20082001;20:740\u2013746","DOI":"10.1097\/00006454-200108000-00005"},{"key":"2021120820020555500_R47","doi-asserted-by":"crossref","unstructured":"Nolan T, Lee M-S, Cordova JM, et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine.\u20082003;21:1224\u20131231","DOI":"10.1016\/S0264-410X(02)00484-X"},{"key":"2021120820020555500_R48","doi-asserted-by":"crossref","unstructured":"Piedra PA. Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children. Semin Pediatr Infect Dis.\u20082002;13:90\u201396","DOI":"10.1053\/spid.2002.122995"},{"key":"2021120820020555500_R49","doi-asserted-by":"crossref","unstructured":"Redding G, Walker RE, Hessel C, et al. Safety and tolerability of coldadapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J.\u20082002;21:44\u201348","DOI":"10.1097\/00006454-200201000-00010"},{"key":"2021120820020555500_R50","doi-asserted-by":"crossref","unstructured":"Gaglani MJ, Piedra PA, Riggs MW, Herschler GB, Griffith ME, Glezen WP. Safety of the trivalent, cold-adapted, influenza virus vaccine (CAIV-T) in a subgroup of children with history of mild intermittent wheezing\/asthma\/reactive airway disease (RAD) in a community-based, non-randomized, open-label trial [Abstract 2437]. Pediatr Res.\u20082001;49:242A","DOI":"10.1016\/S0531-5131(01)00019-X"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/3\/e397\/1005206\/zpe0090500e397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/3\/e397\/1005206\/zpe0090500e397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T09:55:37Z","timestamp":1683194137000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/116\/3\/e397\/68366\/Live-Attenuated-Influenza-Vaccine-Trivalent-Is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,1]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,9,1]]},"published-print":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-2258","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,1]]}}}